10 results
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
14 Jun 24
Condensed Consolidated Financial Statements
4:30pm
indications and focus on the inflammatory and auto-immune verticals, the Company reduced its workforce by approximately 50%. The workforce reductions … as a result of the reduction in workforce as part of the strategic reprioritization plan, a $1,288,000 decrease in expenses for clinical studies and pre
424B5
ENLV
Enlivex Therapeutics Ltd
29 May 24
Prospectus supplement for primary offering
4:15pm
, the Company reduced its workforce by approximately 50%. The workforce reduction and the savings associated with the reclassification of the oncology
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
, including a change to its internal clinical development indications and a related reduction of the Company’s workforce followed by certain
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
and auto-immune verticals, the Company intends to reduce its workforce by approximately 50%. The workforce reductions and the savings associated
6-K
EX-99.1
42hqu2
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
6-K
44tc2j 980m
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
20-F/A
u9cq2q
23 Jan 20
Annual report (foreign) (amended)
4:31pm
- Prev
- 1
- Next